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Abstract
The ACTN3 R577X polymorphism (rs1815739) is a strong candidate to influence elite athletic performance. Yet, controversy
exists in the literature owing to between-studies differences in the ethnic background and sample size of the cohorts, the
latter being usually low, which makes comparisons difficult. In this case:control genetic study we determined the association
between elite athletic status and the ACTN3 R577X polymorphism within three cohorts of European Caucasian men, i.e.
Spanish, Polish and Russian [633 cases (278 elite endurance and 355 power athletes), and 808 non-athletic controls]. The
odds ratio (OR) of a power athlete harbouring the XX versus the RR genotype compared with sedentary controls was 0.54
[95% confidence interval (CI): 0.34–0.48; P= 0.006]. We also observed that the OR of an endurance athlete having the XX
versus the RR genotype compared with power athletes was 1.88 (95%CI: 1.07–3.31; P= 0.028). In endurance athletes, the OR
of a ‘‘world-class’’ competitor having the XX genotype versus the RR+RX genotype was 3.74 (95%CI: 1.08–12.94; P= 0.038)
compared with those of a lower (‘‘national’’) competition level. No association (P.0.1) was noted between the ACTN3 R577X
polymorphism and competition level (world-class versus national-level) in power athletes. Our data provide comprehensive
support for the influence of the ACTN3 R577X polymorphism on elite athletic performance.
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Introduction
One of the most investigated genes with respect to elite athletic
performance is the ACTN3. This gene encodes a-actinin-3, a
sarcomeric protein that is almost exclusively expressed in fast,
glycolytic, type II fibres, where it plays an important role in the
generation of ‘explosive’ powerful contractions [1,2]. A nonsense
polymorphism (rs1815739) was identified in the ACTN3 gene,
which results in replacement of an arginine (R) residue with a
premature stop codon (X) at amino-acid 577 [3]. Approximately
18% of Caucasians are homozygous for the stop codon (i.e. they
harbour the XX genotype) and are completely deficient in a-
actinin-3 [1,4].
The a-actinin-3 knock-out (KO) mouse model was subsequently
developed to explore the biological role of the ACTN3 R577X
polymorphism [5,6]. Compared with their wild- type counterparts,
KO mice show lower and higher activity of the anaerobic and
aerobic pathways respectively [6]. KO mice also exhibit higher
time to fatigue, lower muscle mass and fibre diameter of fast-twitch
(type IIB) muscle fibres, and lower muscular strength [5,6]. These
observations support the hypothesis that the ACTN3 R577X
polymorphism has functional significance in muscle function and
metabolism, and might be influential to elite athletic performance.
However, genetic association studies in cohorts of athletes have
produced contradictory findings.
The ACTN3 R allele, or the RR genotype, has been positively
associated with elite, power-oriented athletic status (e.g. sprinters,
jumpers or throwers) in some [4,7,8,9,10,11,12], but not all
cohorts of Caucasian athletes [13,14]. Similarly, the X allele or the
XX genotype has been positively associated with elite endurance
athletic status [4,7,12], although some studies have not observed a
significant association with endurance phenotypes in non-athletic
[15,16] or athletic cohorts [17,18,19,20,21]. Some of the
contradictory findings may be due to between-study differences
in the competition level of the recruited athletes, which reflects the
absence of a universally-accepted definition of what is considered
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‘elite-level’. The inclusion of mixed-gender populations in previous
studies may also have contributed to between-study differences.
The principal methodological limitation in the field of genetics
and athletic performance is the need for large population samples
(i.e. more than a few hundreds) to reach sufficient statistical power
to allow making solid conclusions [22,23]. Most of the aforemen-
tioned studies performed with elite athletes were limited by a
relatively low sample size (n #200), which is understandable due
to the low number of athletic champions available for analysis.
Thus, multi-centre studies involving athletes from different
nationalities are needed. In the present study, we were able to
recruit over 600 elite male athletes from three different European
countries in an attempt to overcome the sample size limitation.
Therefore, the main aim of the present study was to determine
the association of the ACTN3 R577X polymorphism with both
elite endurance and power athletic status, in a large group of
European Caucasians, consisting of Spanish, Polish and Russian
athletic and non-athletic (controls) men. Additionally, we also
examined the association of the ACTN3 R577X polymorphism
with the level (national-level vs. world-class) of athletic participa-
tion in both endurance and power athlete groups.
Materials and Methods
The study was conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all
participants, and the study was approved by the ethics committees
of Universidad Europea de Madrid, Spain, the Pomeranian Medical
University, Poland, and the Ural State University of Physical
Culture, Russia.
Participants
A total of 633 athletes (278 endurance athletes and 355 power
athletes) and 808 controls, from Spain, Poland and Russia,
volunteered to participate in this study. All participants were
unrelated European males and all Caucasians (as self-reported) for
$3 generations. We included athletes in the study sample only if
they had participated in national/international championships
and they had never tested positive in anti-doping controls.
Inclusion criteria for all control participants were to be free of
any diagnosed cardiorespiratory disease and not engaged in
competitive sports or in formal, supervised exercise training (i.e.
performing less than 3 structured weekly sessions of strenuous
exercise such as running, swimming, bicycling or weight lifting).
Spanish population. The population comprised 273 elite
athletes and 343 controls:
(i) 119 elite power athletes aged 20–33 years, including the best
Spanish volleyball players (n = 66), track and field jumpers (n = 13)
and sprinters (n = 40) in recent years. Thirteen track and field
athletes were Olympians during the period 2000–2008.
(ii) 154 elite endurance athletes aged 20–39 years. This sample
included 50 elite endurance runners (the top Spanish runners
during the 1999–2009 period, i.e. mainly 5,000 m to marathon
specialists, virtually all of them Olympians), 50 professional road
cyclists who were all Tour de France finishers (including stage
winners), and 54 rowers. A total of 39 rowers won at least one
bronze, silver or gold medal in the lightweight category (skip or
scull, including a total of 6 gold medals) in the World
Championships held during 1997–2006.
(iii) 343 healthy, non-athletic controls aged 19–32 years. All
were undergraduate students from the same university (Universidad
Europea de Madrid, Spain).
Polish population. The population comprised 217 elite
Polish athletes and 354 controls:
(i) 105 elite power athletes. This group included weightlifters
(n = 49, including 2 Olympic champions, 3 World champions
(power-lifting) and 10 medallists in World or European champi-
onships), sprinters (#200 m, n= 46, including an Olympic
champion and 9 medallists in Olympic games or World/European
championships), track and field jumpers (n = 6, including an
Olympic champion, and 3 medallists in Olympic Games or
World/European championships), and volleyball players (n = 4, all
medallists in Olympic Games or World/European champion-
ships).
(ii) 112 elite endurance athletes. This group included rowers
(n = 53, including 14 Olympic/Word champions and 22 medallists
in Olympic Games or World/European championships), endur-
ance road cyclists (n = 14, including 7 medallists in Olympic
Games or World/European championships), 5,000 m runners
(n = 12, including 1 Olympic medallist), marathon runners
(n = 12), 800–1,500 m swimmers (n = 11, including 2 medallists
in Olympic Games or World/European championships)), 15–
50 km cross-country skiers (n = 6, including 2 Olympic champi-
ons), and triathletes (n = 4, all are silver or bronze medallist in
European championships).
(iii) 354 healthy sedentary controls aged 19–32 years (all
students of the University of Szczecin).
Russian population. The population sample comprised 143
Russian athletes, and 111 controls:
(i) 125 elite power athletes. This group included: ice hockey
players of the Kontinental Hockey League (KHL), which is the highest
ranked hockey league in Europe (n= 59), skaters competing in
events #1000 m (n= 17, including 3 World champions and 3
European champions), boxers (n = 18, including 8 World cham-
pions and 3 European champions), wrestlers (n = 10, including 3
European champions), swimmers competing in events #200 m
(n= 8), weightlifters (n = 6, including the World Powerlifting
Congress record man), figure skaters (n = 3), shot putters (n = 2),
one strongman (vice-world champion and three times Russia’s
Strongest Man), and one taekwondo specialist.
(ii) 18 elite endurance athletes. This group included rowers
(n = 6), skaters competing in events $5000 m (n= 4), walkers
(n = 4, including one winner of the European Cup), one swimmer
competing in events .200 m (bronze medallist in European
championships, Olympian in 2008), one marathon runner
(European champion), one duathlete, and one water polo player.
According to their individual best performances, we further
divided the athletes within each group into two subgroups: ‘world-
class’, i.e. those who had represented their country in European or
World championships, or in the Olympic Games; and ‘national-
level’, i.e. those who had competed at a national but not
international level (Table 1).
Genotyping
We followed recent recommendations for genotype-phenotype
association studies provided by Chanock et al. [24], Attia et al.
[25], and the latest ‘Strengthening the Reporting of Genetic
Association studies’ (STREGA) group report [26].
Spanish population. Genomic DNA was isolated from
buccal epithelium or peripheral blood during the years 2004–
2008 and genotyping was performed in the Genetics Laboratory of
Universidad Europea de Madrid, Spain. We followed the ACTN3
R577X genotyping methods that were applied in previous
research [27]. The polymerase chain reaction (PCR) was
performed in order to amplify the sequence containing the
mutation. A fragment of 291 bp was amplified with the following
primers: ACTN3-F 59- CTGTTGCCTGTGGTAAGTGGG
labelled a 59 with VIC and ACTN3-R 59- TGGTCACAG-
ACTN3 R577X Polymorphism and European Athletes
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TATGCAGGAGGG. The PCR conditions were as follows: initial
denaturing at 95uC 5 min; 35 cycles at 95uC 30 s, 60uC 30 s,
72uC 30 s and a final extension at 72uC 10 min. ACTN3 genotypes
were established by enzymatic digestion of amplicons with DdeI.
The 25 ml reaction mix consisted of 5 ml aliquot amplified PCR
product, 1X reaction NEB 3 Buffer (New England Biolabs,
Beverly, MA, USA) and 1U of DdeI restriction enzyme (New
England Biolabs, Beverly, MA, USA). The reaction mix was
incubated 1 h at 37uC. The R577X change creates a restriction
site resulting in fragments of 108, 97 and 86 bp. Digestion of the
R577 allele results in fragments of 205 and 86 bp, and digestion of
the 577X allele results in fragments of 108, 97 and 86 bp. The
digestion products detected by capillary electrophoresis (ABI Prism
310 genetic analyzer; Applied Biosystems, Foster City, CA) were
those labelled with VIC, i.e. 108 bp for 577X, and 205 bp for
R577.
Following recent recommendations [24], we replicated the
genotype results of the Spanish cohort (in 40% of samples) in
another laboratory (Progenika Biopharma, Parque Tecnolo´gico de
Zamudio, Vizcaya, Spain) using a different method, i.e. a newly
developed low-density DNA microarray based on allele-specific
probes. The design, fabrication, validation and analysis of the
arrays were performed following the procedure detailed elsewhere
[28] with minor modifications. The PCR products were fluores-
cently labelled and hybridized to the DNA microarray in an
automated platform (Tecan HS4800, Mannedorf, Switzerland).
Finally, the microarrays were scanned (Innopsys S.A., Carbonne,
France) and a software was used which converts the intensity of the
spots into the genotype of the polymorphism.
Polish population. Genomic DNA was isolated from buccal
epithelium using GenElute Mammalian Genomic DNA Miniprep
Kit (Sigma, Germany), during the years 2008–2010, according to
the producer protocol. Genotyping was performed using poly-
merase chain reaction (PCR) as described elsewhere [29]. The
amplified fragment subsequently underwent digestion by DdeI.
The digested products were separated by 3% agarose gel
electrophoresis, stained with ethidium bromide, and visualized in
UV light.
Russian population. Genomic DNA was isolated from
buccal epithelium or peripheral blood, during the years 2009–
2011, using the DiatomTM DNA Prep kit (Cat. # D 1025,
IsoGene Lab Ltd, Russia). The kit is based on selective DNA
absorption on a surface of glass powder in the presence of high
concentration of guanidine isothiocyanate as chaotropic agent.
Genotyping of the ACTN3 R577X polymorphism was per-
formed by using a TaqManH SNP Genotyping Assay (Applied
Biosystems, Foster city, CA, USA) with a StepOneTM Real-Time
PCR System (Applied Biosystems, Foster city, CA, USA). Assay ID
was C____590093_1_. The results were analyzed by using
TaqManH Genotyper Software (Applied Biosystems, Foster city,
CA, USA). For replication purpose, 75% of the samples in the
Russian cohort were analysed with a different method, i.e. PCR-
restriction length polymorphism (RFLP), according to a previously
described method [29]. The oligonucleotide primers for this
method were synthesized by Evrogen Ru JSC (Russia). K562
DNA High Molecular Weight from Promega Corp. (Cat #
DD2011, Madison, WI, USA) served as positive control samples at
carrying out both research methods. Genetic profile of K562 DNA
was XX in the ACTN3 R577X sequence variation.
Statistical Analysis
We used the x2 test to test for the presence of Hardy–Weinberg
equilibrium (HWE). We compared genotypic and allele frequen-
cies in all groups using the Fisher’s exact test, as an omnibus test,
separately by country (Spain, Poland and Russia). We conducted
Table 1. Genotype and allele frequencies of the ACTN3 R577X polymorphism (rs1815739) in male endurance and power athletes,
and in male sedentary controls, from Spain, Poland and Russia.
Spain (n =616) Poland (n =571) Russia (n =254)
Control Endurance Power P* Control Endurance Power P* Control Endurance Power P*
all 343 154 119 0.119 354 112 105 0.465 111 18 125 0.019
RR 106 (30.9) 41 (26.6) 37 (31.1) 140 (39.5) 46 (41.1) 46 (43.8) 39 (35.1) 8 (44.4) 43 (34.4)
RX 175 (51) 73 (47.4) 66 (55.5) 176 (49.7) 56 (50.0) 54 (51.4) 46 (41.4) 10 (55.6) 68 (54.4)
XX 62 (18.1) 40 (26.0) 16 (13.4) 38 (10.7) 10 (8.9) 5 (4.8) 26 (23.4) 0 (0.0) 14 (11.2)
MAF 0.436 0.497 0.412 0.356 0.339 0.305 0.441 0.278 0.384
HWE-P value 0.564 0.938 0.004 0.134 0.290 0.044 0.124 0.242 0.125
World-class 139 119 0.022 68 66 0.203 11 89 0.732
RR 38 (27.3) 37 (31.1) 32 (47.1) 25 (37.9) 5 (45.5) 34 (38.2)
RX 63 (45.3) 66 (55.5) 27 (39.7) 36 (54.5) 6 (54.5) 45 (50.6)
XX 38 (27.3) 16 (13.4) 9 (13.2) 5 (7.6) 0 (0.0) 10 (11.2)
MAF 0.500 0.412 0.331 0.349 0.273 0.365
National-level 15 – – 44 39 0.069 7 36 0.569
RR 3 (20.0) – 14 (31.8) 21 (53.8) 3 (42.9) 9 (25.0)
RX 10 (66.7) – 29 (65.9) 18 (46.2) 4 (57.1) 23 (63.9)
XX 2 (13.3) – 1 (2.3) 0 (0.0) 0 (0.0%) 4 (11.1)
MAF 0.467 0.352 0.231 0.286 0.431
*Fisher’s exact test.
Values are frequency (percent).
HWE: Hardy–Weinberg equilibrium; MAF: minor allele frequency.
doi:10.1371/journal.pone.0043132.t001
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logistic regression analysis to analyse the association between: (i)
ACTN3 R577X polymorphism and athletic status (i.e. power
athlete, endurance athlete, or non-athletic control), and (ii) ACTN3
R577X polymorphism and competition level (national level or
world-class) within each group of power or endurance athletes.
Analyses were adjusted for country of origin. The association of
the polymorphisms with athletic status was evaluated by conduct-
ing the following contrasts: RR (reference group) vs. RX, and RR
vs. XX (co-dominant effect); RR vs. RX and XX combined
(dominant effect); RR and RX combined (reference group) vs. XX
(recessive effect). In addition, we conducted correspondence
analysis with x2 distance and symmetric normalization methods
in order to graphically demonstrate the association between
ACTN3 R577X and athletic status.
All statistical analyses were conducted using the IBM-SPSS (v.
20.0 for WINDOWS, Chicago). A nominal P-value #0.05 was
considered significant.
Results
Replication analysis of the Spanish and the Russian samples
using a different genotyping method was 100% successful. Table 1
show the genotype and allele frequencies of the ACTN3 R577X
polymorphism in all participants. Genotype distributions of all
control and athletic groups were in agreement with the Hardy
Weinberg Equilibrium (all P.0.1), except for the Spanish and
Polish power athletes (P=0.004 and P=0.044 respectively).
Table 2 displays the association of the ACTN3 R577X
polymorphism with athletic status. The odds ratio (OR) of a
power athlete harbouring the XX vs. the RR genotype (co-
dominant effect) compared with sedentary controls was 0.54 [95%
confidence interval (CI): 0.34–0.48; P=0.006]. The results remain
significant when the analysis was further adjusted by type of sport
[OR: 0.33, 95% CI: 0.12–0.93; P=0.036]. The OR of having the
XX genotype vs. having the recessive trait (RR+RX combined)
was 0.52 (95%CI: 0.34–0.78; P=0.002), whereas the association
was attenuated once the analysis was adjusted by type of sport
(OR: 0.68, 95%CI: 0.29–1.59; P=0.379). Compared with
controls, the OR for an endurance athlete to harbour the XX
vs. the RR genotype (co-dominant effect) was 1.18 (95%CI: 0.78–
1.79; P=0.424), whereas the OR of having the XX genotype vs.
having the recessive trait (RR+RX combined) was 1.17 (95%CI:
0.81–1.69; P=0.406). However, when the analyses were adjusted
by type of sport the association became significant (OR: 5.02,
95%CI: 1.89–13.33, P=0.001; and OR: 1.87, 95%CI: 1.16–3.01,
P=0.010). Compared with power athletes, the OR for an
endurance athlete to harbour the XX vs. the RR genotype (co-
dominant effect) was 1.88 (95%CI: 1.07–3.31; P=0.028), whereas
the OR of having the XX genotype vs. having the recessive trait
(RR+RX combined) was 1.89 (95%CI: 1.12–3.14; P=0.016).
Similar results were observed after further adjusting by type of
sport (OR: 3.33, 95%CI: 1.42–7.8, P=0.005; and OR: 2.41,
95%CI: 1.12–5.15, P=0.023, respectively). The findings did not
materially change when the analyses were additionally adjusted by
the athlete’s level of participation (world-class vs. national-level)
(data not shown).
Table 3 shows the association between the ACTN3 R577X
polymorphism and competition level (national-level vs. world-
class), within each group of endurance and power athletes. In
endurance athletes, the OR of a world-class athlete having the XX
genotype vs. having the recessive trait was 3.74 (95%CI: 1.08–
12.94; P=0.038) compared with a national-level athlete. Howev-
er, the association was slightly attenuated once the analysis was
further adjusted by type of sport (OR: 3.28, 95%CI: 0.79–13.62;
P=0.102). In power athletes, we observed no association (P.0.1)
between the ACTN3 R577X polymorphism and competition level
(national-level vs. world-class).
Table 2. The odds ratio of ACTN3 R577X (rs1815739) genotypes for endurance and power athletes.
Controls vs. Endurance vs. Controls vs. Power Power vs. Endurance
RR (ref.) 1.0 1.0 1.0
RX 1.02 (0.75; 1.39) 1.07 (0.81; 1.41) 1.00 (0.69; 1.46)
P 0.897 0.655 0.982
XX 1.18 (0.78; 1.79) 0.54 (0.34; 0.84) 1.88 (1.07; 3.31)
P 0.424 0.006 0.028
RX+XX vs. (RR ref.) 1.06 (0.79; 1.42) 0.93 (0.71; 1.22) 1.14 (0.79; 1.63)
P 0.704 0.617 0.488
XX vs. RR+RX (ref.) 1.169 (0.81; 1.69) 0.52 (0.34; 0.78) 1.89 (1.12;3.14)
P 0.406 0.002 0.016
Data are odds ratio and 95% confidence intervals.
Analysis adjusted by country. Abbreviation: ref., reference group.
doi:10.1371/journal.pone.0043132.t002
Table 3. The odds ratio of ACTN3 R577X (rs1815739)
genotypes for endurance and power athletes, according to
their competition level (world-class vs. national-level).
Endurance Power
RR (ref.) 1.0 1.0
RX 0.41 (0.21; 0.82) 1.05 (0.60; 1.85)
P 0.011 0.864
XX 2.11 (0.28; 8.00) 1.99 (0.61; 6.55)
P 0.272 0.257
RX+XX vs. (RR ref.) 0.52 (0.26; 1.02) 1.13 (0.65; 1.96)
P 0.058 0.667
XX vs. RR+RX (ref.) 3.74 (1.08; 12.94) 1.94 (0.62; 6.07)
P 0.038 0.258
Data are odds ratio and 95% confidence intervals.
Analysis adjusted by country. Abbreviation: ref., reference group.
doi:10.1371/journal.pone.0043132.t003
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Figure 1 graphically shows the correspondence analysis of
athletic status with ACTN3 R577X polymorphism. The first
dimension (i.e. dimension 1, horizontal line) observed accounted
for 94.7% of the total inertia, which indicates that this dimension
almost accounted for all the inertia of the observed data. This
dimension was mainly generated by type = power and by
ACTN3genotype = XX, which accounted for 66.7% and 61.7%
respectively, of the total inertia of this dimension. The power
athletes group and the XX genotype were displayed in the
extremes of the figures, whereas the endurance athletes group was
close to the XX genotype. The percentages of explained variance
of each dimension by the categories are presented in a
supplementary file (Table S1).
Discussion
We studied the association between the ACTN3 R577X
polymorphism and elite athletic status in a large group of elite
male athletes, comprising three cohorts of European Caucasian
male athletes. The main findings of the present study were: (i) elite
power athletes were less likely (,50%) to harbour the XX
genotype compared with sedentary controls; and ii) the ACTN3
XX genotype was more prevalent in endurance athletes, who were
1.88 times more likely to harbour the XX genotype compared
with power athletes, which was further strengthened after
adjusting by type of sport (OR: 3.33). The potential favourable
effect of the XX genotype on elite endurance athletic status was
Figure 1. Correspondence diagram of athlete type with ACTN3 R577X (rs1815739) polymorphism.
doi:10.1371/journal.pone.0043132.g001
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additionally supported by the finding that the chance of a world-
class athlete to have the XX genotype vs. the other genotypes was
,3.7 higher compared with a less successful (national-level)
athletes. However, it must be emphasized that no Russian
endurance athlete had the XX genotype. Reasons for this striking
finding are unclear, although the small sample size of this specific
athlete’s group within the Russian cohort might be a potential
confounder. An additional reason might lie in the lack of athletes
with a ‘pure’ endurance phenotype (e.g. marathoners, cross-
country skiers or triathletes) in the Russian cohort.
We believe that the results of our study are overall valid, as all of
the following criteria were met [25]: cases (athletes) clearly
presented the main study phenotype (i.e. being an elite athlete);
we studied some of the best elite endurance athletes world-wide,
participants within each cohort were ethnically-matched; genetic
assessment was accurate and unbiased; and genotype distributions
were in HWE in the control group of the three cohorts. With
regards to the fact that HWE was not met in the Spanish and
Polish power athletes’ groups, in must be emphasized that, for a
genetic association study with a case-control design as the present
one, attainment of HWE should only be a requirement (and
strictly speaking should only be tested) in the control group,
because they are supposedly representative of the general
population.
A novel finding of the present study is that the XX genotype is
even more favourable for world-class endurance athlete status
compared with national-level endurance athlete status. To date,
only one study, with Israeli athletes [7], showed an association
between the ACTN3 R577X and elite athletic status with respect to
the competition level of the athlete. However, the relatively small
number of elite endurance athletes recruited for the aforemen-
tioned study (n= 20) made it difficult to reach a solid conclusion.
Here, the sub-groups of world-class and national-level endurance
athletes had a larger sample size (n = 218 and n= 66 respectively),
providing support for an association between the ACTN3 XX
genotype and world-class endurance athlete status. This observa-
tion indicates that while this genotype is important in the
development of endurance ability, it might be even more
important in the development of world-class endurance ability.
Mechanistic observations using the a-actinin-3 deficient (KO)
mouse model (i.e. with the XX genotype) provide support for our
results. KO mice show significantly higher activity of mitochon-
drial enzymes, and longer treadmill running, compared with wild-
type mice [1,6]. Isolated KO mice muscles have longer twitch half-
relaxation times and enhanced recovery from fatigue compared
with muscles from wild-type animals, providing a possible
explanation for poorer sprint and improved endurance perfor-
mance in XX humans [1,5,6]. Further support for the association
between the ACTN3 R577X polymorphism and athletic status
relies on the finding that humans with the XX genotype tend to
have a higher percentage of slow-twitch (type I) muscle fibres,
which would benefit endurance performance, whereas RR
homozygotes have a higher percentage of fast-twitch (IIX)
glycolytic muscle fibres, which might favour power-oriented
performance [30]. However, others found that a-actinins do not
play a significant role in determining human skeletal muscle fibre
composition [31]. In KO mice, the cross-sectional area of fast-
twitch (IIB) fibres is 34% smaller compared with wild-type mice
[5]. Interestingly, a smaller diameter of human fast-twitch (IIX)
fibres has been previously correlated with time-trial performance
in endurance athletes (cyclists) [32]. A possible explanation is that
a small diameter of IIX fibres may allow for a greater capillary
density (capillaries/mm2) in these cells, as well as for an enhanced
removal of lactate and H+, which would benefit endurance
performance.
A favourable genetic endowment seems necessary to become an
elite athlete, yet the putative influence of specific candidate genes
on the possibility of becoming an athletic champion, whether
individually or in combination with other variants or environ-
mental factors, requires further investigation. The ACTN3 R577X
polymorphism is probably the most promising candidate gene
among all of the studied athletic status-related genes, and the only
muscle-structural gene showing a genotype:performance associa-
tion. Taken together, and despite some controversy, most notably
in East-African elite distance runners [21], present and previous
findings support an overall favourable association between the
ACTN3 XX genotype and human endurance performance, at least
in those endurance events where the ability to produce explosive
peak power is not a main success determinant.
In conclusion, our findings provide support for an association
between ACTN3 R577X polymorphism and elite athletic status in
a large group of elite male athletes. The findings indicated that the
ACTN3 XX genotype is more prevalent in endurance athletes,
who are more likely to harbour this genotype compared with
power athletes. Future studies are encouraged to recruit large
enough samples of elite athletes from different ethnic and
geographic backgrounds. Therefore, large collaborations and data
sharing between researchers, as presented here, are strongly
recommended. Mechanistic approaches are also encouraged to
explain the observed genotype:phenotype associations.
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